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that threatens global health. The WHO has estimated about 9 million
new tuberculosis (TB) cases and around 1.5 million deaths due to TB
in the year 2013 (World Health Organization, 2014). In MTB-infected
individuals, bacteria may exist in a dormant state for lengthy periods
without causing disease symptoms, or may ﬁnally start multiplying
and evading immune control, resulting in active TB in 5–10% of infected
cases. At present, factors that promote progression from latent tubercu-
losis infection (LTBI) to disease are not totally understood. Therefore,
management of LTBI plays a signiﬁcant role for TB disease control
given that quiescent bacilli are a big reservoir of potential TB cases.
Tuberculin skin test (TST) has been the classical method used for
LTBI diagnosis in spite of its compromised speciﬁcity due to cross-
reactionwithMycobacterium bovis bacillus Calmette–Guérin (BCG) vac-
cine strain and non-tuberculous mycobacteria. Furthermore, it has low
sensitivity in immune compromised patients, who are in particular
those that mainly need this test because they have a high risk of devel-
oping active TB if they are infected. Interferon (IFN)-γ release assays
(IGRAs) appeared more than a decade ago as an alternative method to
TST for diagnosing LTBI. They detect the IFN-γ released by sensitized T
cells after stimulationwith speciﬁc MTB antigens encoded in the region
of difference (RD) 1 and 11 (ESAT-6, CFP-10 and TB7.7) (Andersen et al.,
2000). Nowadays, IGRAs implementation has improved LTBI diagnosis
because of their higher speciﬁcity with respect to TST and good correla-
tion with MTB exposure degree; however, they do not discriminate be-
tween LTBI and active TB (Pai et al., 2014). As a consequence, there is a
need for studying new biomarkers to explore the biology and the im-
mune response for distinguishing latency from disease.
At present, some new MTB phase-dependent antigens have been
studied in LTBI individuals and active TBpatients showing promising re-
sults. These studies explore the response of T cells producing IFN-γ be-
cause they are the major players in the protection against TB. However,
variable results regarding these antigens have been obtained since now
due to disparities in methodology and population heterogeneity
(Serra-Vidal et al., 2014; Goletti et al., 2010; Singh et al., 2014). In
EBioMedicine, Delﬁna Peña and colleagues (Peña et al., 2015) have in-
vestigated the efﬁcacy of several DosR regulon-encoded latency anti-
gens as potential markers for LTBI. The antigens included and studied
in this work were Rv2624c, Rv2626c, and Rv2628; together withDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.05.026.
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tients or healthy controls. In a ﬁrst approach, the response to MTB
antigens was investigated stimulating peripheral blood mononuclear
cells (PBMCs) fromBCG LTBI individuals (QFT-GIT positive) and healthy
controls (QFT-GIT negative), ﬁnding that IFN-γ response was signiﬁ-
cantly higher in LTBI individuals with respect to healthy controls upon
Rv2626c stimulation. Interestingly, these ﬁndings were also conﬁrmed
by ﬂow cytometry. Then, in a second approach, the IFN-γ response to
Rv2626c was also analyzed in a third group of active TB patients stimu-
lating PBMCs and whole blood with this speciﬁc antigen. In contrast to
the results obtained with RD1 antigens (ESAT-6 and CFP-10), stimula-
tion with this latency antigen allowed to discriminate between active
and latent infection since patients with active TB did not secrete IFN-γ
against Rv2626c. Finally, these results were also reinforced by a ROC
analysis. Investigators also identiﬁed several speciﬁc and immunogenic
Rv2626c immunodominant peptide pools that improved LTBI diagnosis.
Delﬁna Peña and colleagues study (Peña et al., 2015) investigates an
interesting and promising ﬁeld; as a consequence, their results are en-
couraging for several reasons. First, as currently IGRAs are not designed
for distinguishing between LTBI and disease; investigations based on
new antigens linked to latency are required. In this sense, the novel
Rv2626c antigen studied in the present work could be promising and
improve LTBI diagnosis. However, further investigations on other
latency antigens different from those contemplated in this study are
still required. Second, the study of new immune-biomarkers for detect-
ing IFN-γ in vitromay open the door to the development of next gener-
ation assays based on new antigens. Furthermore, potential host
biomarkers are urgently needed to provide risk of LTBI progression as
well. In this sense, a recent published study have assessed the utility
of measuring IFN-γ/TNF-α ratio against 16 antigens, ﬁnding that
Rv2626c and Rv3716c improved QFT-GIT diagnostic performance and
LTBI diagnosis (Prabhavathi et al., 2015). In addition, the use of ﬂow cy-
tometry is currently beingutilized for the study of the immune response
and cell surface marker expression (immunophenotyping) in order to
ﬁnd a signature related with infection or disease (Harari et al., 2011;
Portevin et al., 2014). Together these ﬁndings will help to develop and
design novel state-of-the-art techniques for LTBI and active TBdiagnosis
in not so near distant future.Conﬂict of interest
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